InsidersTradesSigma
Track the LIGAND PHARMACEUTICALS INCORPORATED share price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Market capitalisation: €5.8bn. The latest transaction was disclosed on 12 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: OCTAVIO ESPINOZA. Every trade is free.
Analysts rate LIGAND PHARMACEUTICALS INCORPORATED Strong Buy (bullish), based on 10 analysts. Average price target: US$343.80.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
6 of 6 declarations
LIGAND PHARMACEUTICALS INCORPORATED is a biopharmaceutical company focused on developing drugs and technologies for the pharmaceutical and biopharmaceutical industries. It is listed on NASDAQ under the symbol LGND.